- Home
- DATS vs HOTH Comparison
DATS vs HOTH Comparison
Compare DATS & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- HOTH
- Stock Information
- Founded
- DATS 2014
- HOTH 2017
- Country
- DATS United States
- HOTH United States
- Employees
- DATS N/A
- HOTH N/A
- Industry
- DATS Computer Software: Prepackaged Software
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- HOTH Health Care
- Exchange
- DATS Nasdaq
- HOTH Nasdaq
- Market Cap
- DATS 13.4M
- HOTH 16.0M
- IPO Year
- DATS 2021
- HOTH 2019
- Fundamental
- Price
- DATS $2.56
- HOTH $1.44
- Analyst Decision
- DATS
- HOTH Strong Buy
- Analyst Count
- DATS 0
- HOTH 3
- Target Price
- DATS N/A
- HOTH $4.00
- AVG Volume (30 Days)
- DATS 211.3K
- HOTH 745.9K
- Earning Date
- DATS 08-13-2025
- HOTH 05-12-2025
- Dividend Yield
- DATS N/A
- HOTH N/A
- EPS Growth
- DATS N/A
- HOTH N/A
- EPS
- DATS N/A
- HOTH N/A
- Revenue
- DATS $388.00
- HOTH N/A
- Revenue This Year
- DATS N/A
- HOTH N/A
- Revenue Next Year
- DATS N/A
- HOTH N/A
- P/E Ratio
- DATS N/A
- HOTH N/A
- Revenue Growth
- DATS N/A
- HOTH N/A
- 52 Week Low
- DATS $1.04
- HOTH $0.58
- 52 Week High
- DATS $9.34
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- DATS 48.61
- HOTH 62.68
- Support Level
- DATS $2.58
- HOTH $1.17
- Resistance Level
- DATS $2.85
- HOTH $1.34
- Average True Range (ATR)
- DATS 0.14
- HOTH 0.10
- MACD
- DATS 0.00
- HOTH 0.02
- Stochastic Oscillator
- DATS 50.89
- HOTH 77.27
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).